Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

2023186 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet

Volume 403, Issue 10421, pp. 31-43

Field-Weighted Citation Impact: 43.08